Loncar Cancer Immunotherapy ETF (CNCR) 은(는) 상장 기업입니다 금융 섹터의 Asset Management 산업에서 운영.
CNCR 을(를) 보유 IPO 날짜 2015-10-14, 에 상장 NASDAQ Global Market, 시가총액 $7.04M.
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
